JPS58154548A - アズレン誘導体の安定化方法 - Google Patents

アズレン誘導体の安定化方法

Info

Publication number
JPS58154548A
JPS58154548A JP57037411A JP3741182A JPS58154548A JP S58154548 A JPS58154548 A JP S58154548A JP 57037411 A JP57037411 A JP 57037411A JP 3741182 A JP3741182 A JP 3741182A JP S58154548 A JPS58154548 A JP S58154548A
Authority
JP
Japan
Prior art keywords
starch
sodium
solvent
gasn
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57037411A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0150226B2 (enExample
Inventor
Masanobu Kawamata
川真田　正信
Koichi Ushimaru
牛丸　紘一
Hiroyuki Goshi
合志　博之
Hidemoto Miyasako
宮迫　秀元
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to JP57037411A priority Critical patent/JPS58154548A/ja
Priority to DE8383102097T priority patent/DE3361520D1/de
Priority to EP83102097A priority patent/EP0088958B1/en
Priority to KR1019830000949A priority patent/KR900003452B1/ko
Priority to US06/473,452 priority patent/US4533552A/en
Publication of JPS58154548A publication Critical patent/JPS58154548A/ja
Publication of JPH0150226B2 publication Critical patent/JPH0150226B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
JP57037411A 1982-03-09 1982-03-09 アズレン誘導体の安定化方法 Granted JPS58154548A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP57037411A JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法
DE8383102097T DE3361520D1 (de) 1982-03-09 1983-03-03 Stabilization of azulene derivatives
EP83102097A EP0088958B1 (en) 1982-03-09 1983-03-03 Stabilization of azulene derivatives
KR1019830000949A KR900003452B1 (ko) 1982-03-09 1983-03-09 아줄렌 유도체의 안정화 방법
US06/473,452 US4533552A (en) 1982-03-09 1983-05-11 Stabilization of azulene derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57037411A JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法

Publications (2)

Publication Number Publication Date
JPS58154548A true JPS58154548A (ja) 1983-09-14
JPH0150226B2 JPH0150226B2 (enExample) 1989-10-27

Family

ID=12496774

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57037411A Granted JPS58154548A (ja) 1982-03-09 1982-03-09 アズレン誘導体の安定化方法

Country Status (5)

Country Link
US (1) US4533552A (enExample)
EP (1) EP0088958B1 (enExample)
JP (1) JPS58154548A (enExample)
KR (1) KR900003452B1 (enExample)
DE (1) DE3361520D1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1201383A (en) * 1983-11-18 1986-03-04 Warner-Lambert Canada Inc. Antacid composition and process for its preparation
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US7448375B2 (en) 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1034327B (de) * 1957-08-30 1958-07-17 Chemiewerk Homburg Ag Verfahren zur Herstellung stabiler Praeparate, wie Puder, Tabletten, Dragees u. dgl., mit einem Gehalt an guajazulensulfo-sauren Salzen
US3833757A (en) * 1972-04-10 1974-09-03 Computer Television Inc Electronic bilateral communication system for commercial and supplementary video and digital signaling
DE3173600D1 (en) * 1980-05-20 1986-03-13 Mallinckrodt Inc Spray dried n-acetyl-p-aminophenol compositions and method for manufacture thereof
JPS57108012A (en) * 1980-12-25 1982-07-05 Ota Seiyaku Kk Preparation of pharmaceutical preparation containing sodium azulenesulfonate
US4395422A (en) * 1981-04-06 1983-07-26 Basf Wyandotte Corporation Spray dried vitamin E powder

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative

Also Published As

Publication number Publication date
EP0088958A1 (en) 1983-09-21
KR840004121A (ko) 1984-10-06
JPH0150226B2 (enExample) 1989-10-27
US4533552A (en) 1985-08-06
EP0088958B1 (en) 1985-12-18
KR900003452B1 (ko) 1990-05-19
DE3361520D1 (de) 1986-01-30

Similar Documents

Publication Publication Date Title
US4699927A (en) Anticonvulsant valproic acid salts
CA1040532A (en) Process for producing solid bismuth-containing pharmaceutical compositions
US4956386A (en) Pharmaceutical compositions and process for their preparation
US4127647A (en) Process for preparation of stable amorphous macrolide antibiotic solids
US5952383A (en) Pharmaceutical composition for oral delivery
JPH0215029A (ja) キノリジノン化合物またはその塩を含有する抗潰瘍剤
JPS60158197A (ja) 抗生物質およびその製法
JPS58154548A (ja) アズレン誘導体の安定化方法
US4066787A (en) Stabilized prostaglandin composition and the process for the preparation thereof
JPS58154547A (ja) アズレン誘導体の安定化法
US4532253A (en) Oxaprozin calcium salt pharmaceutical compositions
IL129140A (en) The use of an antifungal gel with the release of a high active ingredient for the preparation of a pharmaceutical preparation for the treatment and prevention of cutaneous fungus
CA1063936A (en) Preparation of amorphous solid of macrolide antibiotics
JPH0222225A (ja) 胃酸分泌抑制剤含有固型製剤
GB2061111A (en) Long acting pharmaceutical composition
JPH01102021A (ja) 局所投与用効果持続性炎症抑制剤組成物
JPS6019893B2 (ja) 抗潰瘍剤
US4338311A (en) Hydrophilic choline salicylate formulation
CN110742271B (zh) 山药活性组分在制备肠粘膜损伤改善剂中的用途及其应用
US3887706A (en) N6-(3-Chlorobuten-2-yl)-adenosines as anti-inflammatory agents
JP3485941B2 (ja) アズレン誘導体の安定な製剤およびその製造方法
JPS5942318A (ja) 製薬組成物、その製造法及び応用
US3642993A (en) Pharmaceutical composition containing 2-methyl - 5 - phenyl - 1 2-dihydro-3h-2-benzazepine for treatment of a condition associated with anxiety or tension
JPH0322874B2 (enExample)
GB2097389A (en) Oxazole derivative